Ignite Creation Date:
2025-12-25 @ 4:50 AM
Ignite Modification Date:
2026-01-26 @ 9:22 PM
Study NCT ID:
NCT00981318
Status:
TERMINATED
Last Update Posted:
2015-06-23
First Post:
2009-09-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
Sponsor:
Rodwick, Barry M., M.D.
Organization:
Study Overview
Official Title:
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc in Experienced Patients
Status:
TERMINATED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
unable to enroll expected number of subjects
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PALM
Brief Summary:
This is a study to assess the response of lopinavir/ritonavir plus maraviroc (with no nucleoside medications) in HIV patients failing their initial antiviral therapy.
Detailed Description:
As long-term toxicity to many of the nucleoside medications have become known, interest has increased in treatment regimens that do not use these medications. This study is to assess the response of one such "nucleoside-sparing" therapy in patients who are showing failure to their initial nucleoside-containing treatment regimen.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: